World's ‘oldest baby' born from embryo frozen in 1994
Thaddeus Daniel Pierce was born on 26 July in Ohio to Lindsey and Tim Pierce, using an 'adopted' embryo from Linda Archerd, 62, from more than 30 years ago.
In the early 1990s, Archerd and her then husband decided to try in vitro fertilisation (IVF) after struggling to become pregnant. In 1994 four embryos resulted – one was transferred to Archerd and resulted in the birth of a daughter, who is now 30 and mother to a 10-year-old. The other embryos were cryopreserved and stored.
'We didn't go into it thinking we would break any records,' Lindsey told the MIT Technology Review, which first reported the story. 'We just wanted to have a baby.'
IVF is a type of fertility treatment where eggs are retrieved from a woman's ovaries and fertilised with sperm in a laboratory setting. The resulting embryos are then transferred back into the womb. The embryos can also be frozen and stored for future use.
Archerd was awarded custody of the embryos after divorcing her husband. She then found out about embryo 'adoption', a type of embryo donation in which both donors and recipients have a say in whom they donate their embryos to.
Archerd had a preference for her embryo to be 'adopted' by a white, Christian married couple, leading to the Pierces adopting the embryo.
'We had a rough birth, but we're both doing well now,' Lindsey said. 'He is so chill. We are in awe that we have this precious baby.'
Archerd said: 'The first thing that I noticed when Lindsey sent me his pictures is how much he looks like my daughter when she was a baby. I pulled out my baby book and compared them side by side, and there is no doubt that they are siblings.'
The fertility clinic that implanted the embryo is run by John Gordon, a reproductive endocrinologist and reformed presbyterian who is working to reduce the number of embryos in storage.
Speaking of the embryo transfer, Gordon said: 'We have certain guiding principles, and they're coming from our faith. Every embryo deserves a chance at life and that the only embryo that cannot result in a healthy baby is the embryo not given the opportunity to be transferred into a patient.'
In the UK the proportion of IVF births has increased from 1.3% in 2000 to 3.1% in 2023, the equivalent of one in 32 UK births, roughly one child in every classroom.
For women aged 40 to 44, 11% of UK births were a result of IVF, up from 4% in 2000, accounting for 0.5% of all births, according to the Human Fertilisation and Embryo Authority (HFEA). In the US, about 2% of births are from IVF.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
an hour ago
- Daily Mail
Vaccine on RFK Jr's chopping block could protect against one of the deadliest cancers
Experimental mRNA vaccines shrouded in controversy may protect against one of America's deadliest cancers, a new study suggests. Researchers across the country tested a personalized mRNA vaccine on people with pancreatic cancer who had already had surgery and still had traces of the disease remaining. Pancreatic cancer is one of the hardest forms of the disease to treat, with a five-year survival rate of just 12 percent. And most cases are diagnosed after the disease has ravaged other organs, as it symptoms are usually mistaken for more benign issues. The vaccine uses mRNA technology, which uses RNA to tell cells how to make proteins and induce an immune reaction, to targets mutations of the KRAS gene. KRAS mutations are thought to be responsible for nine in 10 pancreatic cancers and nearly half of colon cancers. The researchers, from major institutions like Memorial Sloan Kettering Cancer Center in New York City and the University of California, Los Angeles (UCLA), found about 85 percent of participants had an immune response to the vaccine. And two-thirds had enough of a response to stave off lingering cancer cells. Participants also lived more than twice as long after getting the vaccine than pancreatic cancer patients on average. Dr Zev Wainberg, trial leader and co-director of the UCLA gastrointestinal oncology program, told NBC News: 'That far exceeds the rates with resectable cancers.' Resectable cancers are those than can be removed with surgery. mRNA technology, which is also used in Covid vaccines, has been hailed a 'game-changer' in the cancer space, leading to a mountain of new trials testing if it can be used in vaccines. In one research paper out of Penn State College of Medicine, the scientists note: 'mRNA vaccines are an attractive and powerful immunotherapeutic platform against cancer because of their high potency, specificity, versatility, rapid and large-scale development capability, low-cost manufacturing potential, and safety.' Despite expert consensus and scientific evidence, however, Health Secretary Robert F Kennedy Jr, a longtime vaccine skeptic, has repeatedly cast doubt on the safety and efficacy of mRNA vaccines. Earlier this month he announced the Department of Health and Human Services (HHS) would cancel nearly $500million in contracts for new vaccine development, including those for mRNA shots. Pancreatic cancer affects roughly 67,000 Americans every year and kills about 52,000. Along with colon cancer, it is also increasingly affecting young people. More than half the time, the disease is first spotted after it has already reached stage three or four due to its vague symptoms. These include abdominal pain, weight loss, back pain, jaundice and floating or clay-colored stools. This leads patients to assume their symptoms are from more benign causes like irritable bowel syndrome (IBS). By the time it reaches stage four, the five-year survival rate is just three percent, making it virtually incurable. It's unclear exactly what causes pancreatic cancer, but smoking, obesity and diabetes are thought to increase the risk by inducing harmful inflammation that causes cells to divide and become mutated more easily. In the new phase I trial, published Monday in the journal Nature Medicine, doctors recruited 20 people with pancreatic cancer and five with colorectal cancer. All participants had a KRAS mutation and had undergone standard treatment, which usually includes chemotherapy and surgery, to shrink and remove most of their tumors. Blood tests revealed the patients had traces of cells left behind, known as microscopic residual disease, which can travel elsewhere in the body and grow into tumors. After surgery, each participant received up to six doses of the vaccine, called ELI-002 2P, and 13 also received booster shots. The team found 85 percent, or 21 out of 25 participants, showed an immune response to the vaccine, and about 66 percent had enough of an immune response to stave off lingering cancer cells. And in nearly 70 percent of participants, the vaccine triggered an immune response not just to KRAS mutations but to other tumor cell targets not in the vaccine. The phase 1 trial also showed people with pancreatic cancer survived for an average of 29 months and lived recurrence-free for 15 months. The average survival length for patients with stage four pancreatic cancer, which is when most are diagnosed, is usually just six months to a year. The team is now running a phase 2 trial to test the vaccine's durability and compare if it is more effective than the current standard of care, which involves monitoring for disease recurrence.
Daily Mail
3 hours ago
- Daily Mail
Urgent recall for popular soap over fears of DEADLY sickness that can cause organ damage
A skincare brand that markets antiseptic soaps to immunocompromised Americans and healthcare workers issued an urgent recall over risks of sepsis and organ failure from its products. DermaRite Industries, LLC, based in New Jersey, found that several of its antiseptic cleansers were contaminated with the bacteria Burkholderia cepacia, a dangerous bacteria that preys on people with weakened immune systems, particularly those with cystic fibrosis (CF). CF is a genetic disorder that causes severe lung damage and makes patients vulnerable to lasting infections. Around 40,000 Americans have the disease, with about 1,000 new cases diagnosed each year, mostly in children under two. 'In healthy individuals with minor skin lesions the use of the product will more likely result in local infections, whereas in immunocompromised individuals the infection is more likely to spread into [the] blood stream leading to life-threatening sepsis,' the FDA said. B. cepacia resists most antibiotics, spreads easily through respiratory droplets from coughing or sneezing and can trigger a fast-moving, often fatal pneumonia called 'cepacia syndrome.' Even CF patients with mild symptoms can develop this aggressive infection. About one in five people with CF who carry the bacteria will progress to severe illness, sometimes with life-threatening bloodstream infections. In addition to people with cystic fibrosis, immunocompromised people who have sickle cell anemia, are being treated for cancer, and being treated for burns, are most at risk of severe infection caused by B. cepacia. The products being recalled are sold under the brands DermaRite, DermaKleen, Dermasarra, Kleenfoam and Perigiene. They were were distributed both to consumers via Amazon and their website and to healthcare facilities, including hospitals and clinics To date, DermaRite has not received any reports of infections linked to their products and it has not been revealed how the products became contaminated. The FDA recommends that people and stores that received shipments of the products 'examine available inventory and destroy all affected products.' DermaKleen is an antiseptic hand soap with Vitamin E that reduces skin bacteria. DermaSarra relieves itching from minor skin irritations like dryness, insect bites, or sunburn. KleenFoam is an antimicrobial foam soap with aloe vera for handwashing after diaper changes, caring for the sick, or before medical contact. PeriGiene is an antiseptic cleanser designed for perineal hygiene. 'Burkholderia Cepacia Complex in these products may result in serious and life-threatening infections,' the FDA said. Scientists call B. cepacia the 'chronic colonizer,' because once it infects the lungs of someone with CF, it persists for life, resisting antibiotics and the body's immune system. It can evade treatment with most common antibiotics, but some, including Bactrim, meropenem, or ceftazidime, have been shown to be effective. But there is no established, universal treatment for the infection. Doctors typically combine oral antibiotics to those administered through an IV. Even then, success is not guaranteed. The bacteria sickens around 20 percent of CF patients. It can spread throughout the body and cause Cepacia syndrome (CS), a severe form of pneumonia that kills lung tissue with a mortality rate approaching 75 percent. In some cases, it can spread beyond the lungs, resulting in multi-system organ failure and death. The bacteria can spread from person to person through droplets emitted when a person coughs or sneezes. It can contaminate medical equipment in hospitals, while also appearing in moist areas in the home, including sinks and humidifiers. From 2004 through 2021, there have been four recalls of nasal sprays that infected patients in the ICU, and a recall mouthwash that caused a cluster of pneumonia. It was also found in a liquid stool softener and an ultrasound gel that affected multiple batches and was recalled. Most healthy individuals will never know that they were infected with this bacteria. But case studies of B. cepacia infections in immunocompromised patients describe severe respiratory distress causing shallow breathing and low oxygen saturation. Patients have also exhibited cracking sounds in their lungs, indicating aggressive infection there, potentially leading to respiratory failure. Early signs of sepsis include fever, a rapid heart rate, fast or shallow breathing, and confusion. As sepsis advances, it causes severe chills and sweating, extreme weakness, low blood pressure, pale skin, and high white blood cell counts.
Reuters
3 hours ago
- Reuters
Texas sues Eli Lilly for allegedly bribing providers to prescribe its medications
WASHINGTON, Aug 12 (Reuters) - Texas Attorney General Ken Paxton on Tuesday sued U.S. drugmaker Eli Lilly (LLY.N), opens new tab for allegedly "bribing" providers to prescribe its medications. The attorney general's office said in a statement the company bribed and illegally induced medical providers to prescribe its most profitable drugs, including the GLP-1 medications Mounjaro and Zepbound that are used for weight loss and diabetes treatment.
